{"id":"pf-06882961-cohort-3","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"Warfarin","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"P-glycoprotein inhibitors","action":"Monitor","effect":"Increased tacrolimus concentrations"},{"drug":"P-glycoprotein inducers","action":"Monitor","effect":"Decreased tacrolimus concentrations"},{"drug":"Strong CYP3A4 inhibitors","action":"Monitor","effect":"Increased tacrolimus concentrations"},{"drug":"Strong CYP3A4 inducers","action":"Monitor","effect":"Decreased tacrolimus concentrations"}],"commonSideEffects":[],"contraindications":["Personal or family history of medullary thyroid cancer (MTC)","Multiple endocrine neoplasia syndrome type 2","History of pancreatitis","Severe gastroparesis","Serious allergic reaction to ingredients","Pregnancy","Nursing","Current or past history of eating disorders","Depression or other mood disorders","History of gallstones"],"specialPopulations":{"Pregnancy":"Females who were pregnant, breastfeeding, or planning to become pregnant while participating in the study were ineligible.","Geriatric use":"text","Paediatric use":"text","Renal impairment":"text","Hepatic impairment":"text"}},"trials":[],"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-06882961-cohort-3","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:40:49.018789+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:40:54.508887+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:40:49.092733+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06882961-cohort-3","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:40:55.068419+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Glucagon-like peptide 1 receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:40:56.524523+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4518483/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:40:56.175570+00:00"}},"allNames":"pf-06882961 (cohort 3)","offLabel":[],"timeline":[],"aiSummary":"PF-06882961 is a marketed drug by Pfizer Inc. for non-small cell lung cancer. It has 3 trials and 0 publications. The mechanism of action is not specified. PF-06882961 is a key treatment option for non-small cell lung cancer. Its clinical differentiation and commercial significance are not well established. There are no pipeline developments mentioned.","brandName":"PF-06882961 (Cohort 3)","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Not specified","novelty":"Not specified","modality":"Not specified","drugClass":"Not specified","explanation":"","oneSentence":"","technicalDetail":"The mechanism of action for PF-06882961 is not specified in the available information. This lack of detail makes it challenging for healthcare professionals to understand the drug's effects and potential interactions. Further research is necessary to determine the technical details of PF-06882961's mechanism of action."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"commercial":{"annualCostUS":"Generic pricing varies by manufacturer","genericStatus":"Generic — off-patent","peakSalesEstimate":"Not publicly reported"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-06882961-cohort-3","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06882961-cohort-3","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:40:57.900104+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"SAXENDA","company":"Novo Nordisk","advantage":"Liraglutide is a GLP-1 receptor agonist, similar to danuglipron (PF-06882961)"},{"name":"WEGOVY","company":"Novo Nordisk","advantage":"Semaglutide is a GLP-1 receptor agonist, similar to danuglipron (PF-06882961)"}],"genericName":"pf-06882961-cohort-3","indications":{"approved":[{"name":"Non-small cell lung cancer","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06567327","phase":"PHASE1","title":"A Study to Learn How the Study Medicine Danuglipron is Taken Up Into the Blood and If Danuglipron Changes How the Body Processes Other Study Medicines (Atorvastatin and Rosuvastatin) in Healthy Adults Who Are Overweight or Obese","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-08-28","conditions":"Obesity","enrollment":82},{"nctId":"NCT04707313","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-01-29","conditions":"Obesity","enrollment":628},{"nctId":"NCT03309241","phase":"PHASE1","title":"First In Human, Single Escalating Oral Dose Study Of PF-06882961 In Healthy Adult Subjects","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-10-17","conditions":"Healthy Subjects","enrollment":25}],"_emaApprovals":[{"date":"","name":"PF-06882961 (Cohort 3)","status":"Authorised","regulator":"EMA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL4518483","moleculeType":"Small molecule","molecularWeight":"555.61"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL4518483"},"formularyStatus":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"Not specified","firstApprovalDate":"","enrichmentLevel":3,"visitCount":8,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:40:57.900104+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}